Move to topTop
January 14, 2022

Terumo Aortic today announced the first commercial implant of a RelayPro Thoracic Stent-Graft System developed through its "Upon Request" program in the United States.

With the "Upon Request" program, there are approximately 2000 stent-graft configurations approved by the US Food and Drug Administration (FDA) which allow physicians significantly more solutions to better fit the anatomical needs of each individual patient. These configurations offer devices that can taper from a larger diameter on top of the device and tapering down by as much as 18mm at the bottom, or a smaller diameter on top and flaring by as much as 18mm larger on the bottom.

The first commercial implant of an "Upon Request" RelayPro device was undertaken by Mazin Foteh MD, Vascular Surgeon, Heart Hospital of Austin, Texas. Dr Foteh commented: "The opportunity to tailor the stent-graft system to precisely match the anatomy of the patient was hugely valuable as it allowed me to accommodate a big gap of the proximal and distal diameters with a single device. This first procedure was very successful, the device performed exactly as expected, and the patient is making a good recovery."

Paul Kuznik, President of Terumo Aortic North America commented: "This first "Upon Request" implant represents another significant milestone for our RelayPro range and emphasises our commitment to delivering the most comprehensive device portfolio within the aortic space and our vision for individualised treatment."

RelayPro is the only lower profile device with a Non-Bare Stent design available in the United States to treat aneurysms and penetrating atherosclerotic ulcers, and received FDA approval in 2021; it is integral to Terumo Aortic's market leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.

About Terumo Aortic

At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be personalised for every patient. We are further complementing our implantable deviceportfolio through the development of digital technologies.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.